期刊文献+

抗苗勒管激素临床研究应用新进展 被引量:22

New progress of anti-Müllerian in clinical research and application
原文传递
导出
摘要 抗苗勒管激素(anti-Müllerian hormone,AMH)是女性重要的生殖生理调节因子之一,主要由卵巢窦前卵泡及小窦状卵泡颗粒细胞分泌,不受促性腺激素的调节,能抑制卵泡的募集、选择,优势卵泡的发育。由于其血清浓度在整个月经周期中保持相对稳定,可在周期任意时刻检测,因此在多囊卵巢综合征(PCOS)、卵巢过度刺激综合征(OHSS)的诊断及治疗过程中具有重要价值;此外,对于卵巢储备功能、体外受精-胚胎移植(IVF-ET)妊娠率、卵巢肿瘤治疗效果及预后的评价也有一定的价值,为肿瘤随访提供了可靠依据。 Anti-Müllerian hormone (AMH) is one of important regulation factors of the female reproductive physiological. It is mainly secreted by the preantral follicles and small antral follicles and out-controlled by the gonadotropins (Gn), could inhibit the recruitment, chosen of follicles, and development of the advantage follicles. Because of its relatively stable serum level throughout the whole menstrual cycle and could be detected any time in the menstrual, AMH has an important value in diagnosing and treatment of polycystic ovary syndrome (PCOS) and ovarian hyperstimulation syndrome (OHSS); furthermore, it has a certain value in ovarian reserve function, pregnancy rates of in vitro fertilization embryo transfer (IVF-ET) and ovarian tumor, also provides a reliable basis for ovarian tumor’s follow-up.
出处 《中华生殖与避孕杂志》 CAS CSCD 北大核心 2017年第6期507-510,共4页 Chinese Journal of Reproduction and Contraception
关键词 抗苗勒管激素(AMH) 卵巢储备功能 多囊卵巢综合征(PCOS) 体外受精/卵胞质内单精子注射(IVF/ICSI)结局:卵巢肿瘤 Anti-Mtillerian hormone (AMH) Ovarian reserve function Polycystic ovary syndrome (PCOS) In vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcome Ovarian tumor
  • 相关文献

参考文献5

二级参考文献73

  • 1赵晓明,毛宇红,刘芳荪,孙赟,洪燕,林其德.卵巢储备功能测定在体外受精(IVF)技术中的临床价值探讨[J].生殖与避孕,2005,25(8):465-468. 被引量:13
  • 2Long WQ, Ranchin V, Pautier P, et al. Detection of minimal levels of serum anti-miillerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab, 2000, 85(2):540-4.
  • 3Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum miillerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril, 2002, 77(3): 468-71.
  • 4Kansal Kalra S, Ratcliffe S, Gracia CR, et al. Randomized controlled pilot trial of luteal phase recombinant FSH stimulation in poor responders. Reprod Biomed Online, 2008, 17 (6):745-50.
  • 5Golan A, Ron-EI R, Herman A, et al. OHSS: an update review. Obstet Gynecol Surv,1989, 44(6):430-40.
  • 6Deffieux X, Antoine JM. Inhibins, activins and anti Mullerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine. Gynecol Obstet Fertil, 2003, 31(11):900-11.
  • 7Rajpert-DeMeyts E, Jorgensen N, Graem N, et al. Expression of anti-Mtillerian hormone during normal and pathological gonadal development association with differentiation of Sertoli and granulose cells. J Clin Endocrinol Metah, 1999, 84 (10):3836-44.
  • 8Baarends WM, Uilenbroek JT, Kramer P. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development,the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology, 1995, 136(10):4951-62.
  • 9Hazout A, Bouchard P, Seifer DB, et al. Serum antimullerian inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril, 2004, 82(5): 1323-9.
  • 10Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod, 2008, 23(6): 1359-65.

共引文献117

同被引文献181

引证文献22

二级引证文献142

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部